NDAINTRAVENOUSSOLUTION
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
COMBOGESIC IV (acetaminophen and ibuprofen injection) by Hikma is cyclooxygenase inhibitors [moa]. Approved for nonsteroidal anti-inflammatory drug [epc], moderate to severe pain, less. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBOGESIC IV is a fixed-dose combination intravenous injection combining acetaminophen and ibuprofen for moderate to severe pain management. It acts as a cyclooxygenase inhibitor with nonsteroidal anti-inflammatory properties, delivered as an IV solution for rapid systemic onset. This dual-mechanism analgesic targets patients requiring acute pain control in hospital and surgical settings.
Growth9.6 years to LOE
Early-stage product in active growth phase with significant commercial team expansion opportunity and minimal competitive pressure.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications (2)
Worked on COMBOGESIC IV at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.